<DOC>
	<DOCNO>NCT00684593</DOCNO>
	<brief_summary>This study conduct : 1 ) ass clinical effect Navarixin Psoriasis Activity Severity Index ( PASI ) , 2 ) determine effect Navarixin Physician 's Global Assessment ( PGA ) , 3 ) evaluate safety tolerability Navarixin , 4 ) determine multiple-dose pharmacokinetics Navarixin .</brief_summary>
	<brief_title>A Study Assess Clinical Effects Navarixin Participants With Psoriasis ( MK-7123-009 )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Body Mass Index ( BMI ) 19 34 , BMI = weight ( kg ) /height ( m^2 ) . Must diagnosis psoriasis vulgaris ( PASI &gt; 8 ) present least 1 year . Participants ontherapy PASI &lt; =8 Screening may consider inclusion . Participants must discuss Sponsor prior enrollment subject must indicate satisfied current therapy . To include , participant must PASI &gt; 8 follow washout current psoriasis therapy . Target lesion select must locate head , trunk , arm legs least 10 cm^2 size . The lesion 's total numerical rating erythema , infiltration , desquamation must least 6 possible 12 . Severity score desquamation must least 2 . Vital sign measurement ( take ~3 minute supine position ) must within follow range : oral body temperature 35.0°C 37.5°C ; systolic blood pressure , 90 160 mm Hg ; diastolic blood pressure , 45 90 mm Hg ; pulse rate , 40 100 bpm . Have stable disease ( ie , treatment PASI Screening period Baseline PASI differ 40 % ) . Clinical laboratory test ( CBC , blood chemistry , urinalysis ) must within normal limit clinically acceptable investigator/sponsor . Participants must neutrophil count least 2 x 10^9/L include . Free clinically significant disease ( psoriasis ) . Willing give write informed consent able adhere dose visit schedule . For female participant : Negative serum pregnancy test ( betahCG ) urine pregnancy test . Agree use medically accept method contraception appropriate prestudy period receive protocol specify medication , 1 month stop medication . Female participant nonchildbearing potential must surgically sterilize postmenopausal . Male subject must agree use adequate form contraception duration study . At Screening , ECG conduction interval must within gender specific normal range ( ie , QTc males &lt; 430 msec female &lt; 450 msec ) within normal range , value must consider clinically insignificant investigator sponsor . Female participant pregnant , intend become pregnant ( within 3 month end study ) , breastfeed . Participants , opinion investigator , able participate optimally study . Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug . History infectious disease within 4 week prior drug administration and/or positive hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) . Immunocompromised participant . Positive screen drug high potential abuse history drug alcohol abuse past 2 year . History mental instability treat mood disorder . Donated blood past 60 day . Previous treatment study medication . Currently participate another clinical study participate clinical study within 30 day . Part study staff personnel family member study staff personnel . Demonstrated clinically significant ( require intervention ) allergic reaction know allergic component local anesthetic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>